Life Sciences

Glenmark Issues Recall of Almost 1.5M Bottles of Generi...

The drug company Glenmark Pharma, which is located in India and has been the sub...

BioNTech’s Malaria Vaccine Trial Temporarily Suspended ...

The U.S. Food and Drug Administration (FDA) has placed a hold on BioNTech’s phas...

Regeneron Shifts Strategy for Lymphoma Bispecific, Focu...

Regeneron has adjusted its regulatory approach for odronextamab, opting to pursu...

Teleflex Restructures Amidst €760 Million Biotronik Dea...

Teleflex has announced plans to restructure its operations by creating two indep...

Silence Therapeutics Halts Zerlasiran Phase 3 Despite 8...

Silence Therapeutics recently shared an update regarding its zerlasiran program,...

FDA Cancels Flu Vaccine Advisory Meeting, Raising Concerns

The Food and Drug Administration (FDA) has canceled its advisory panel meeting o...

Roche Comes Out With Novel ‘Sequencing-By-Expansion’ Ap...

Roche has proposed a fresh kind of genetic analysis. This process, which the com...

6yMirum’s Ctexli surpasses FDA milestone for rare metab...

After Mirum Pharmaceuticals spent $210 million to acquire Travere Therapeutics’ ...

MeiraGTx Gene Therapy Shows Promise in Restoring Vision...

Eleven children who were born legally blind experienced significant improvements...

Eli Lilly Lowers Zepbound Prices and Expands Dosage Opt...

Eli Lilly has announced a reduction in the price of vials for its obesity medica...

Former Inizio Evoke Executives Launch Flex Marketing

A group of former executives from health communications firm Inizio Evoke have l...

Biogen Secures Ex-U.S. Rights to Dravet Syndrome Treatment

Biogen has bolstered its research and development efforts by securing an agreeme...

FDA Approves Romvimza for Treatment of Tenosynovial Gia...

The U.S. Food and Drug Administration (FDA) has approved Romvimza (vimseltinib) ...

FDA Approves Penmenvy Vaccine for Meningococcal Disease...

The U.S. Food and Drug Administration (FDA) has approved Penmenvy, a vaccine for...

Bristol Myers Cuts Off Allergy Asset In Spite of Phase ...

Bristol Myers Squibb has persisted with its aggressive cost-reduction strategy, ...

Biogen secures $250 million to finance phase 3 study

To forward a significant pipeline opportunity, Biogen has secured $250 million. ...